Home
Live Updates
CatalYm GmbH: CatalYm Commences Phase 2 Development of GDF-15-Targeting Antibody CTL-002 Following Successful Phase 1 Completion : comparemela.com
CatalYm GmbH: CatalYm Commences Phase 2 Development of GDF-15-Targeting Antibody CTL-002 Following Successful Phase 1 Completion
CatalYm receives International Nonproprietary Name (INN) visugromab for CTL-002 as approved by the World Health Organization CatalYm today announced treatment of the first patients in a series of
Related Keywords
Spain ,
Germany ,
Switzerland ,
Kostenloser Wertpapierhandel ,
Catalym Gmb ,
Phil Lhuillier ,
Ignacio Melero Center ,
World Health Organization ,
International Nonproprietary Name ,
Trophic Communications ,
Differentiation Factor ,
Ted Human Effector ,
Ignacio Melero ,
Advanced Medical Research ,
Principal Investigator ,
Eugen Leo ,
Chief Medical Officer ,
Phill Huillier ,
Growth Differentiation ,
Laura Mittmann ,
Stephanie May ,
Catalym ,
Mbh ,
Ommences ,
Hase ,
Development ,
Targeting ,
Ntibody ,
Following ,
Uccessful ,
Completion ,
comparemela.com © 2020. All Rights Reserved.